Neuroscience

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

Parkinson's disease
#Japan #Neurodegenerative disorders #Parkinson's

Research reveals therapeutic target for Parkinson’s 

Researchers in Japan have revealed a potential new therapeutic target for Parkinson’s disease.  Scientists at Juntendo University found that liquid droplets of the protein ubiquilin-2 act as a catalyst for the aggregation of a-synuclein, a protein in the brain which is associated with neurodegenerative disorders. Ubiquilin-2 droplets… Read More

#News

RNA
#Amyotrophic lateral sclerosis (ALS) #Gene therapy #Neurodegenerative disorders #Tel Aviv University

RNA-based gene therapy offers new hope for ALS treatment

A team of researchers have uncovered a previously unknown molecular mechanism that drives the progression of amyotrophic lateral sclerosis (ALS) and succeeded in neutralising it using RNA-based gene therapy.   The study was conducted in the laboratory of Professor Eran Perlson from the Gray Faculty of Medical &… Read More

#Editor's Choice #News

Neuronal network
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

eBook: What’s new in neuroscience drug discovery?

The global neuroscience market has grown significantly in the last 10 years, driven predominantly by an ageing population and increasing cases of neurodegenerative diseases like Alzheimer’s disease (AD). The neuroscience market size was estimated at $44.65 billion in 2023 and is projected to reach $65.22 billion by 2030,… Read More

#News

#Alzheimer's #GLP-1 #Neurodegenerative disorders #Novo Nordisk #Obesity

Semaglutide shows no benefit in Alzheimer’s disease

Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer’s disease progression.  The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic… Read More

#Business & Investment #News #Trending News

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

DDW Highlights: 18 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, groundbreaking research showed the Covid-19 mRNA vaccine could boost cancer response. Elsewhere,… Read More

#Podcasts

Brain physiology
#Alzheimer's #Investment #Neurodegenerative disorders

Scripta raises $12 million to find disease-modifying drugs 

UK techbio company Scripta Therapeutics has announced it has raised $12 million to find disease-modifying drugs altering transcription factor activity.  The financing round was led by by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advisors, with support from Oxford University Innovation. Read More

#Business & Investment #News

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

This week in Drug Discovery (10 – 14 November) 

News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW.  This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective… Read More

#News

Antibiotics
#Antibiotics #Mental health #Psychiatry #Schizophrenia

Antibiotic doxycycline shown to reduce schizophrenia risk

A commonly prescribed antibiotic could help reduce the risk of some young people developing schizophrenia, new research suggests.  Experts found that patients of adolescent mental health services who were treated with the antibiotic doxycycline were significantly less likely to go on to develop schizophrenia in adulthood compared… Read More

#News

Neurons
#Dementia #Neurodegenerative disorders #Parkinson's #Peptides #University of Bath

Scientists design peptide ‘switch’ to slow Parkinson’s progress

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of alpha-synuclein, a protein linked to Parkinson’s disease and related dementias.   The team has successfully demonstrated it works in an animal model… Read More

#News #Trending News

Dementia
#Dementia #Neurodegenerative disorders #Phase II trial #Vesper Bio

First oral therapy for frontotemporal degeneration shows promise

Positive topline results from Vesper Bio’s Phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic carriers with frontotemporal degeneration (FTD) caused by mutations in the progranulin gene (GRN).  Mean progranulin levels increased by more than 95% compared to baseline at the highest dose tested.   As… Read More

#Editor's Choice #News

#Neuroscience

Whitepaper – Navigating Neurological Biomarker Research: Progress, Learnings and Future Directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology.   Brought to… Read More

#Whitepapers

Human brain
#Alector #Dementia #Neurodegenerative disorders #Phase III trial

Alector discontinues dementia drug and cuts staff by 49%

Alector has revealed that in a Phase III clinical trial in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) its candidate latozinemab (AL001) did not meet the clinical co-primary endpoint.  Based on the results, the company has announced that the open-label extension portion of… Read More

#Business & Investment #News

#Neuroscience #NRG Therapeutics

NRG Therapeutics announces senior appointments

Neuroscience company NRG Therapeutics has announced an expansion to its senior team as it advances its neurodegenerative disease treatment NRG5051.  Sarah Almond has been appointed as VP of Translational Biology, David Brocklebank as Director of Clinical Operations, and Kathryn Oliver as Director of Project Management. … Read More

#News

Brain physiology
#Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early-stage advances in Parkinson’s drug discovery

A number of key clinical and preclinical study results into potential Parkinson’s disease (PD) therapeutics were announced at the International Congress of Parkinson’s Disease and Movement Disorders.  Unexpected early results for allosteric enzyme modulator Gain Therapeutics shared encouraging early results from the Phase Ib… Read More

#Exclusive Content